Ascendis Pharma A/S banner

Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 222.15 USD 2.19%
Market Cap: $13.4B

Wall Street
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 277.84 USD with a low forecast of 227.25 USD and a high forecast of 359.1 USD.

Lowest
Price Target
227.25 USD
2% Upside
Average
Price Target
277.84 USD
25% Upside
Highest
Price Target
359.1 USD
62% Upside
Ascendis Pharma A/S Competitors:
Price Targets
IPAR
Inter Parfums Inc
10% Upside
QLYS
Qualys Inc
33% Upside
HOTH
Hoth Therapeutics Inc
531% Upside

Revenue
Forecast

30% / Year
Past Growth
63% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat
30% / Year
Past Growth
63% / Year
Estimated Growth
Estimates Accuracy
4%
Average Beat

For the last 11 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 30%. The projected CAGR for the next 4 years is 63%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASND's stock price target?
Price Target
277.84 USD

According to Wall Street analysts, the average 1-year price target for ASND is 277.84 USD with a low forecast of 227.25 USD and a high forecast of 359.1 USD.

What is Ascendis Pharma A/S's Revenue forecast?
Projected CAGR
63%

For the last 11 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 30%. The projected CAGR for the next 4 years is 63%.

Back to Top